about
Stability and in vitro metabolism of dipeptide model prodrugs with affinity for the oligopeptide transporter.hPEPT1 affinity and translocation of selected Gln-Sar and Glu-Sar dipeptide derivatives.SGLT1-mediated Transport in Caco-2 Cells Is Highly Dependent on Cell Bank Origin.Discovery of ligands for the human intestinal Di-/Tripeptide transporter (hPEPT1) using a QSAR-assisted virtual screening strategy.Delivery aspects of small peptides and substrates for peptide transporters.Imidazole-4-acetic acid, a new lead structure for interaction with the taurine transporter in outer blood-retinal barrier cells.In vitro solubility, dissolution and permeability studies combined with semi-mechanistic modeling to investigate the intestinal absorption of desvenlafaxine from an immediate- and extended release formulation.Interactions between organic anions on multiple transporters in Caco-2 cells.A quantitative structure-activity relationship for translocation of tripeptides via the human proton-coupled peptide transporter, hPEPT1 (SLC15A1)A comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE).Dipeptide derivatives of AZT: synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity.Novel wound models for characterizing ibuprofen release from foam dressings.Phe-Gly dipeptidomimetics designed for the di-/tripeptide transporters PEPT1 and PEPT2: synthesis and biological investigations.Epidermal growth factor and insulin short-term increase hPepT1-mediated glycylsarcosine uptake in Caco-2 cells.Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line.Epidermal growth factor inhibits glycylsarcosine transport and hPepT1 expression in a human intestinal cell line.Model prodrugs for the intestinal oligopeptide transporter: model drug release in aqueous solution and in various biological media.Model prodrugs designed for the intestinal peptide transporter. A synthetic approach for coupling of hydroxy-containing compounds to dipeptides.Prodrugs of purine and pyrimidine analogues for the intestinal di/tri-peptide transporter PepT1: affinity for hPepT1 in Caco-2 cells, drug release in aqueous media and in vitro metabolism.Factors that restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part I. Role of efflux transporters in the intestinal mucosa.Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa.Acyclovir prodrug for the intestinal di/tri-peptide transporter PEPT1: comparison of in vivo bioavailability in rats and transport in Caco-2 cells.Impact of carriers in oral absorption: Permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide.New insights into the carrier-mediated transport of estrone-3-sulfate in the Caco-2 cell model.Stability, metabolism and transport of D-Asp(OBzl)-Ala--a model prodrug with affinity for the oligopeptide transporter.Wheat germ agglutinin-functionalised crosslinked polyelectrolyte microparticles for local colon delivery of 5-FU:in vitroefficacy andin vivogastrointestinal distributionConformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugsDevelopment of a QSAR Model for Binding of Tripeptides and Tripeptidomimetics to the Human Intestinal Di-/Tripeptide Transporter hPEPT1In vitro evaluation of N-methyl amide tripeptidomimetics as substrates for the human intestinal di-/tri-peptide transporter hPEPT1Design, synthesis, and evaluation of tripeptidic promoieties targeting the intestinal peptide transporter hPEPT1Dipeptidomimetic ketomethylene isosteres as pro-moieties for drug transport via the human intestinal di-/tripeptide transporter hPEPT1: design, synthesis, stability, and biological investigationsImpact of transporters in oral absorption: a case study of in vitro and in vivo organic anion absorptionEstimating intestinal absorption of inorganic and organic selenium compounds by in vitro flux and biotransformation studies in Caco-2 cells and ICP-MS detectionSimulating kinetic parameters in transporter mediated permeability across Caco-2 cells. A case study of estrone-3-sulfateInteraction between fed gastric media (Ensure Plus®) and different hypromellose based caffeine controlled release tablets: comparison and mechanistic study of caffeine release in fed and fasted media versus water using the USP dissolution apparatusPolysorbate 20 alters the oral bioavailability of etoposide in wild type and mdr1a deficient Sprague-Dawley ratsThe Permeation of Acamprosate Is Predominantly Caused by Paracellular Diffusion across Caco-2 Cell Monolayers: A Paracellular Modeling ApproachNonionic surfactants increase digoxin absorption in Caco-2 and MDCKII MDR1 cells: Impact on P-glycoprotein inhibition, barrier function, and repeated cellular exposureNonionic surfactants modulate the transport activity of ATP-binding cassette (ABC) transporters and solute carriers (SLC): Relevance to oral drug absorption
P50
Q31416109-259D21C2-FF1E-44EE-A96C-9D0EA7936A05Q33216422-6AE0BB32-A03D-4384-AEDF-9191B4FC32C2Q33459228-0BED16EE-5F33-427E-8856-D39D935807D7Q33474995-563CCB0E-32F8-4490-8F62-660657241821Q36134559-E877E902-52E5-45CD-ABE0-B1651488D978Q38713893-6294A27F-39C3-463D-88D6-D204CE0FACA2Q38862155-CAF0F78D-56D6-46A2-B5A8-3762457D7E37Q39537380-E721AAF2-72CE-4D64-A386-0DB1EEDBD315Q39706601-F23A0023-E4A7-4AA5-AE4F-798A5CAA6C44Q39929250-B0469B52-CB40-4D24-B4B4-14EC980EA271Q39994950-7873EFDD-F34D-442C-B31B-26A8E07BC858Q40056029-58DF24AD-3667-4C2E-8C41-E367FA762DF9Q40592833-B3BDBEB1-DC4B-4882-8048-0B11B7EF9D46Q40643423-F93130B6-1632-4B30-8FB5-8D18D4FF1809Q40782816-B9B4B83A-B9B7-461A-8C71-2BE2F6D39ACEQ40799214-F56B01DE-DF9F-4CAA-8976-B1294420E863Q43597565-212A7687-1ED6-47EE-ABE2-92F617BC84E5Q43678463-ECFB21FF-BE80-4E68-A9B0-05A934C33A8BQ44277341-696AB2DF-8CC2-4FE1-BB26-B7381A121537Q44339039-5E678229-C2A2-469E-94AD-AB07B4ED773BQ44339043-DEFE74FC-3481-40AA-9463-B53F19472BDAQ45164840-D85ED0B6-9F66-4DF4-AE38-2A186C2BCDCCQ45985464-101C0108-F500-452A-8FBE-D23B6BCD6C7EQ50852663-BD976FC0-C6EC-40BA-B923-7820C6D48EE6Q52222028-7AE14473-1A98-4D34-9868-6CCAD65DACF9Q57349920-0871A82B-2C17-47C2-BA62-04B61B6E3076Q61621851-216A9B86-014C-4C07-BA0B-DD0B5C0CA49EQ62648677-652ED8EA-9A91-4522-9FB8-A32CE0B94FCBQ62648683-0688471B-1FF8-4986-A4FA-C43DC0056102Q80094731-EAB08D5E-BE7E-46B8-B03C-4B942790CD4FQ80515413-E66B4911-5BC1-4783-AAC1-4A6B25017E56Q84112041-F8EDECB0-A4C2-4A81-B1B1-D46442604B51Q84814914-E7E7A639-4D14-4C2E-8E70-C68D01269A7DQ84882826-0F1DF2D6-560A-4EB1-901E-FF6B703A2859Q86957075-A138C9E1-277F-4B87-AA0D-6538C485A574Q88318562-75300D67-B190-4D8C-94F6-233ACF6BFDB4Q90328575-099A4B3C-9E1C-4758-9D31-D6533D418A0BQ91627269-458932FE-589B-4047-9C9B-6DDE49285310Q92272815-13F23672-3113-4CEB-8599-43799292310D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bente Steffansen
@ast
Bente Steffansen
@en
Bente Steffansen
@es
Bente Steffansen
@nl
type
label
Bente Steffansen
@ast
Bente Steffansen
@en
Bente Steffansen
@es
Bente Steffansen
@nl
prefLabel
Bente Steffansen
@ast
Bente Steffansen
@en
Bente Steffansen
@es
Bente Steffansen
@nl
P108
P106
P108
P1153
6603735768
P31
P496
0000-0002-5016-1246